Clinical trials: Neoantigen
Non Small Cell Lung Cancer
Clinical Study of Neoantigen Vaccine Combined With Targeted Drugs in the Treatment of Non-small Cell Lung Cancer
Neoantigen vaccine is a new field of research in tumor immunotherapy, and some studies have been conducted with success on Melanoma and glioblastoma.
- Trial name
- NCT04487093
- Testing
- neoantigen vaccine + EGFR-TKI, neoantigen vaccine + anti-angioge
- Where
- China
- Volunteers
- 20 people
- Sponsor
- First Hospital of Shijiazhuang City
Gastrointestinal Cancer
Safety, Tolerance and Preliminary Efficacy of XH001 Injection Combined With Neoantigen Vaccine-induced Tumor-specific T-cell Injection in Advanced Gastrointestinal Cancer
The goal of this clinical trial is to learn the safety of tumor neoantigen vaccine combined with neoantigen vaccine induced T-cell in treating advanced gastrointestinal cancer in adults.
- Trial name
- NCT07329894
- Testing
- XH001 injection, Tumor vaccine-induced specific T-cell injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Beijing GoBroad Hospital
Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma
Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load
This phase II trial studies how well durvalumab and olaparib work in treating prostate cancer in men predicted to have specific genetic mutations (a high neoantigen load).
- Trial name
- NCT04336943
- Testing
- Durvalumab, Olaparib, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Washington
Metastatic Melanoma
A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma
The primary purpose of this study is to demonstrate that the NEO-PV-01 vaccine, either with APX005M or ipilimumab, and nivolumab is safe for the treatment of patients with advanced or metastatic melanoma.
- Trial name
- NCT03597282
- Testing
- NEO-PV-01, Nivolumab, Adjuvant
- Where
- 8 sites in United States
- Volunteers
- 22 people
- Sponsor
- BioNTech US Inc.
Breast Cancer, Triple Negative Breast Cancer
Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant Therapy
This is a pilot protocol to evaluate the safety, feasibility, and immunogenicity of a personalized breast cancer vaccine based utilizing whole exome sequencing data of a patient's residual breast tumor following neoadjuvant…
- Trial name
- NCT06435351
- Testing
- Leukapheresis, Dendritic Cell (DC) Vaccine
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Melanoma
ATL001 in Patients With Metastatic or Recurrent Melanoma
This is a first-in-human, open-label, multi-centre, phase I/IIa study to characterize the safety and clinical activity of ATL001, autologous clonal neoantigen reactive T cells (cNeT) administered intravenously in adults with…
- Trial name
- NCT03997474
- Testing
- ATL001, Checkpoint Inhibitor
- Where
- 10 sites in Spain, United Kingdom
- Volunteers
- 13 people
- Sponsor
- Achilles Therapeutics UK Limited
Pancreatic Cancer Resectable
Personalized Tumor Neoantigen MRNA Therapy Adjuvant Treatment for Postoperative Pancreatic Cancer.
This study is a single-center, open-label clinical study to evaluate the feasibility and safety of personalized tumor neoantigen mRNA therapy (iNeo-Vac-R01) in combination with PD-1 antibody and standard chemotherapy regimen as…
- Trial name
- NCT06888674
- Testing
- individualized anti-tumor new antigen iNeo-Vac-R01 injection, Gemcitabine + Capecitabine, Sintilimab injection
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Zhejiang University
Non-small Cell Lung Cancer
MIDRIXNEO-LUNG Dendritic Cell Vaccine in Patients With Non-small Cell Lung Cancer
MIDRIXNEO-LUNG is a novel autologous dendritic cell vaccine for non-small cell lung cancer patients, targeting neoantigens predicted from the patient-individual tumor's mutanome.
- Trial name
- MIDRIXNEO (NCT04078269)
- Testing
- Dendritic cell immunotherapy, Antigen-specific DTH, Control DTH
- Where
- Belgium
- Volunteers
- 6 people
- Sponsor
- University Hospital, Ghent
Advanced Malignant Solid Tumor
Neoantigen Reactive T Cells Combined With SHR-1210 for Chinese Patients With Advanced Refractory Solid Tumors
The purpose of this study is to see the safety and efficient of neoantigen reactive T cells (NRTs) combined with programmed cell death-1(PD-1) inhibitor（SHR-1210）in the treatment of Chinese patients with advanced refractory solid…
- Trial name
- NRT-01 (NCT03171220)
- Testing
- Neoantigen Reactive T Cells(NRTs), SHR-1210, Fludarabine
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Non Small Cell Lung Cancer
FRAME-001 Personalized Vaccine in NSCLC
Despite encouraging results of programmed cell death protein -1 (PD-1) immune checkpoint inhibitor treatment combined with chemotherapy in advanced non-small cell lung cancer (NSCLC), only the minority of approximately 20% of…
- Trial name
- NCT04998474
- Testing
- FRAME-001 personalized vaccine
- Where
- 3 sites in Netherlands
- Volunteers
- 15 people
- Sponsor
- Frame Pharmaceuticals B.V.
Advanced Cancer
Safety and Tolerability Study of AutoSynVax™ Vaccine in Subjects With Advanced Cancer
Open-label Phase 1 study of AutoSynVax™ vaccine with QS-21 Stimulon® adjuvant in subjects with advanced cancer
- Trial name
- NCT02992977
- Testing
- AutoSynVax™ vaccine
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Agenus Inc.
Advanced NSCLC
Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment
In this study, the investigators provide a combined treatment of personalized tumor neoantigen-based peptide vaccine, PD-1 Inhibitor, and radiotherapy to patients with advanced non-small cell lung cancer (NSCLC) progressed after…
- Trial name
- NCT06752044
- Testing
- Radiotherapy, PD-1 inhibitor, Neoantigen-based peptide vaccine
- Where
- 2 sites in China
- Volunteers
- 10 people
- Sponsor
- The First Affiliated Hospital of Nanchang University
Adrenal Cortical Carcinoma, Medullary Thyroid Cancer
Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)
Treatment of advanced endocrine tumors, including adrenal corticocarcnioma (ACC), medullary thyroid carcinoma (MTC), thymic neuroendocrine tumor and pancreatic neuroendocrine tumor is challenging.
- Conditions
- Adrenal Cortical Carcinoma, Medullary Thyroid Cancer, Thymic Neuroendocrine Carcinoma, Pancreatic Neuroendocrine Tumor
- Trial name
- NCT06141369
- Testing
- individualized mRNA neoantigen vaccine (mRNA-0523-L001)
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Resectable Pancreatic Cancer
Personalized Neoantigen Vaccine in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy
This research study is evaluating a new type of pancreatic cancer vaccine called "Personalized Neoantigen Cancer Vaccine" as a possible treatment for pancreatic cancer patients following surgical resection and adjuvant…
- Trial name
- NCT04810910
- Testing
- iNeo-Vac-P01, GM-CSF
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Zhejiang Provincial People's Hospital
Carcinoma, Non-Small-Cell Lung
Personalized DC Vaccine for Lung Cancer
The study is aimed to the test the efficacy and safety of neoantigen-primed dendritic cell (DC) cell vaccine therapy for refractory non-small cell lung cancer.
- Trial name
- SKLB1608 (NCT02956551)
- Testing
- DC vaccine
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Sichuan University
Melanoma, Advanced Non Small Cell Lung Cancer
Long-Term Follow-Up Study of Patients Receiving ATL001
This is an Open-Label, Multi-Centre Phase II study to evaluate the long-term safety and clinical activity of ATL001, previously administered intravenously to patients in Study ATX-NS-001 (NCT04032847) or Study ATX-ME-001…
- Trial name
- NCT04785365
- Testing
- Biological: ATL001
- Where
- United Kingdom
- Volunteers
- 1 people
- Sponsor
- Achilles Therapeutics UK Limited
Neoplasms
Pilot Study of Neoantigen Peptides for the Treatment of Neoplasms
This research is a pilot clinical trial using personalized neoantigen peptide vaccines with an adjuvant (Montanide ISA-51 VG), in patients with different types of cancer
- Trial name
- NCT04509167
- Testing
- Neoantigen Peptides
- Where
- Mexico
- Volunteers
- 30 people
- Sponsor
- Instituto de Medicina Regenerativa
Advanced Malignant Solid Tumor
Clinical Study of a Personalized Neoantigen Cancer Vaccine in Treating Patients With Advanced Malignant Tumor
This research study is evaluating a new type of cancer vaccine called "Personalized Neoantigen Cancer Vaccine" as a possible treatment for advanced malignant tumor.
- Trial name
- NCT03662815
- Testing
- iNeo-Vac-P01, GM-CSF
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sir Run Run Shaw Hospital
Pancreas Cancer, Pancreas Cancer, Duct Cell Adenocarcinoma
A Study of mRNA Vaccines AK154 Monotherapy or in Combination With AK104/AK112,and Sequential mFOLFIRINOX in Surgically Resected PDAC
To explore safety and efficacy of neoantigen personalized mRNA vaccines AK154 monotherapy or in combination with AK104/AK112 and sequential mFOLFIRINOX regime in Resected PDAC
- Trial name
- NCT06913218
- Testing
- AK154, Cadonilimab, Ivonescimab (SMT112 or AK112) Injection
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Akeso
Solid Tumor
Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02)
The primary objective of this study is to evaluate the safety of Neo-T in the treatment of advanced solid tumors. The secondary objective of this study is to evaluate preliminarily the effect of Neo-T in the treatment of advanced…
- Trial name
- NCT05798546
- Testing
- Neo-T, Cyclophosphamide, Fludarabine
- Where
- China
- Volunteers
- 21 people
- Sponsor
- BGI, China